I was about to say OM an upgrade! But it's an assume coverage. ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald 07:53 PRQR Cantor Fitzgerald analyst…
Van we have been out of WOLF since it broke my cost of around $100! Just letting you know. It's funny because it' on my buy look today list! Are you back on the THOR team? Did you re buy w/ me? WOLF-
Well YETI has triggered the alert. It's not a buy yet, we'll wait for the mid $30's ______________________________ STONEY!!!! This is why you shouldn't use "analysts", and only use VZ: >>>Roth Capital Adjusts YETI Holdings' Price Target to $48 From $80, Maintains Neutral Rating MT Newswires · 05/12/2022 03:09 >>>>Jefferies Adjusts YETI Holdings' Price Target to $121 From $120, Reiterates Buy Rating MT Newswires · 05/12/2022 01:55
A good sign? The analysts are slowly easing up we got a great LNG PT upgrade but that's energy we got an assume of coverage with a buy and now we have this: ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald 07:53 PRQR Cantor Fitzgerald analyst… Aw Fuck- another " assume " I didn't spot that...
Van! There you are what's with the Cramer stuff I couldn't follow along? I've decided to make peace with Cramer I sent him an email this morning.
BBIO POSSIBLE GUMMY> Holley reports Q1 EPS 18c, consensus 15c » 07:43 HLLY Reports Q1 revenue… BridgeBio announces license agreement with Bristol-Myers for BBP-398 07:42 BBIO, BMY BridgeBio Pharma (BBIO) announced an exclusive license with Bristol Myers Squibb (BMY) to develop and commercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology. Under the terms of the agreement, BridgeBio will receive an upfront payment of $90M, up to $815M in development, regulatory and sales milestone payments, and tiered royalties in the low- to mid-teens. BridgeBio will retain the option to acquire higher royalties in the United States in connection with funding a portion of development costs upon the initiation of registrational studies. Based on the terms of the agreement, BridgeBio will continue to lead its ongoing Phase 1 monotherapy and combination therapy trials. Bristol Myers Squibb will lead and fund all other development and commercial activities. "We are grateful to be expanding our collaboration with Bristol Myers Squibb, a leader in oncology, and we believe this agreement will allow us to reach even more patients with difficult-to-treat cancers. We believe our SHP2 inhibitor has the potential to be a best-in-class agent given the data we have seen, and we are eager to see our monotherapy and combination trials progress in collaboration with our partners at Bristol Myers Squibb," said Neil Kumar, Ph.D., founder and CEO of BridgeBio.
Ya wanna know why I get nasty? Because of stuff like that. Read the posts and don't ask stupid questions. I wrote my current thoughts on THOR. And we missed your post where you exited WOLF Isn't that what you said to me yesterday about whatever stock it was?
GUMMY ALERT**** BUY IN THE PRE IF YOU CAN BridgeBio Pharma, Inc. (BBIO) @$5.45 5.21-0.84 (-13.88%) At close: May 11 04:00PM EDT 5.45 +0.24 (+4.61%) Pre-Market: 08:27AM EDT
I wrote: 2 weeks ago I started talking about Thor. Everyone knows they make Airstreams. I only mentioned it a dozen times, and now you just realize this? Gimmee a break Stoney. Tell me you're not that clueless. I called it out at $75 in a huge bear market and it went to $89.60. I rode it too. To $84.50. I made a dozen posts, and you mocked it. Did you effing read any of them? Yes, Thor makes Airstream dipsh**. How can you mock a pick without even looking? I made over a dozen posts and covered the retro love in depth. Do I like it now... its ok. The headwinds are still there and I think it'll see the low $70's again. Maybe lower.